Clinical trials: Liver Tumour
HCC - Hepatocellular Carcinoma
Eparlitozoviril as Adjuvant Therapy for Resectable HCC With MVI
Tumor recurrence is the leading cause of death and a major bottleneck for long-term survival in patients with hepatocellular carcinoma (HCC).
- Trial name
- Ad-rHCC (NCT07658105)
- Testing
- eparlitozoviril, Control group
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma, Programmed Cell Death 1
Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCC
China is a high-risk area of Hepatocellular Carcinoma (HCC). Although Chinese population accounts for 18.4% of the global population, the number of new HCC patients accounting for about half of the global, which seriously…
- Conditions
- Hepatocellular Carcinoma, Programmed Cell Death 1, Effects of Immunotherapy
- Trial name
- NCT05420922
- Testing
- Lenvatinib Oral Product, PD-1 inhibitor, Local treatment
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Tongji Hospital
Carcinoma, Hepatocellular
Harms of Hepatocellular Carcinoma Surveillance
This study leverage a multi-center randomized controlled trial assessing screening-related benefits (i.e. early tumor detection, treatment eligibility, and overall survival) among a racially and socioeconomically diverse…
- Trial name
- NCT03756051
- Testing
- Prospective Longitudinal Data, Surveys and Semi-structured Interviews
- Where
- United States
- Volunteers
- 2,871 people
- Sponsor
- University of Texas Southwestern Medical Center
Hepatocellular Carcinoma, Non-cirrhotic Liver
Liver Transplantation for Hepatocellular Carcinoma Arising in Non-cirrhotic Liver: a Propensity Score-matched Retrospective Cohort Study of Two National Databases
Background: Majority of liver transplantation (LT) recipients for hepatocellular carcinoma (HCC) were concomitant with liver cirrhosis, while few researches focusing on recipients without cirrhosis.
- Trial name
- NCT06364839
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Xiao Xu
Hepatocellular Carcinoma
Cytoreductive Surgery and Transarterial Chemoembolization (TACE) Versus TACE for Hepatocellular Carcinoma
The aim of this study is to compare the surgical outcomes of cytoreductive surgery followed by Transarterial Chemoembolization (TACE) with TACE alone in patients with MNHCC so as to establish a treatment standard for MNHCC.
- Trial name
- TACE (NCT00820157)
- Testing
- Cytoreductive Surgery, TACE
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Breast Cancer, Liver Cancer
Theranostic Approach by Early Multigene Sequencing in Advanced Poor Prognosis Cancers
The European Society for Medical Oncology (ESMO) strongly recommends to develop multigene sequencing in the framework of molecular screening programmes, in order to improve access to innovative drugs and to accelerate clinical…
- Conditions
- Breast Cancer, Liver Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- ESCAT (NCT06958224)
- Testing
- Large and early multigene sequencing
- Where
- France
- Volunteers
- 360 people
- Sponsor
- University Hospital, Lille
Melanoma, Carcinoma, Hepatocellular
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
The Phase 1b part of this study is conducted to assess the safety and tolerability of E7386 in combination with pembrolizumab in participants with previously treated selected solid tumors, and to determine the recommended Phase 2…
- Conditions
- Melanoma, Carcinoma, Hepatocellular, Colorectal Neoplasms
- Trial name
- NCT05091346
- Testing
- E7386, Pembrolizumab, Lenvatinib
- Where
- 32 sites in United States, Japan and 2 more
- Volunteers
- 89 people
- Sponsor
- Eisai Inc.
Liver Cancer, Recurrence
Factors Influencing the 3-Year Recurrence of Liver Carcinoma After Surgery
Objective: 1. To study the factors that influence the 3- year recurrence of liver carcinoma after surgery 2. To study the related factors affecting recurrence of liver carcinoma after surgery
- Trial name
- NCT02941861
- Testing
- Recurrence Rate of HCC after surgery, Recurrence Rate of CCA after surgery
- Volunteers
- 67 people
- Sponsor
- Ruechuta Molek
Hepatocellular Carcinoma, Hepatocellular Cancer
Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria
Patients with hepatocellular carcinoma (HCC) beyond Milan Criteria (MC) who are undergoing evaluation for or waitlisted for liver transplantation will be treated with 6 months of neoadjuvant/downstaging atezolizumab plus…
- Trial name
- NCT05185505
- Testing
- Atezolizumab, Bevacizumab
- Where
- 2 sites in United States, Canada
- Volunteers
- 24 people
- Sponsor
- The Methodist Hospital Research Institute
Metastatic Cancer, Congestive Heart Failure
Reducing Disparities in the Quality of Advance Care Planning for Older Adults
This study compares the effectiveness of two different approaches to advance care planning among older African Americans and older Whites living in the community.
- Conditions
- Metastatic Cancer, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, Parkinson Disease
- Trial name
- EQUALACP (NCT03516994)
- Testing
- Respecting Choices First Steps, Five Wishes Form
- Where
- 4 sites in United States
- Volunteers
- 790 people
- Sponsor
- Duke University
HCC - Hepatocellular Carcinoma
Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
The purpose of this study is to learn how well a combination of iparomlimab and tuvonralimab (QL1706), lenvatinib, radiotherapy, and hepatic arterial infusion chemotherapy (HAIC) works and how safe it is for people with…
- Trial name
- NCT07776080
- Testing
- Iparomlimab and Tuvonralimab (QL1706), Lenvatinib, Radiotherapy
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Hepatocellular Carcinoma(HCC), Cirrhotic Portal Hypertension
Optimal Treatment on Hepatocellular Carcinoma (HCC) With Cirrhotic Portal Hypertension
There is no consensus about the optimal treatment of hepatocellular carcinoma (HCC) with cirrhotic portal hypertension, While this group of patients are classified as hepatectomy contraindication according to guidelines from…
- Trial name
- NCT01642446
- Testing
- Precise hepatectomy, Combined intervention (chemoembolization/ablation)
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Radiofrequency Ablation Using Octopus Electrodes for Treatment of Focal Liver Malignancies: Follow-up Study
The purpose of this study is to compare the therapeutic outcomes and safety of the study patients who received radiofrequency ablation (RFA) using separable clustered electrodes with those of a matched historical control group…
- Trial name
- NCT02745483
- Testing
- Separable clustered electrodes
- Where
- South Korea
- Volunteers
- 153 people
- Sponsor
- Seoul National University Hospital
Colorectal Cancer Metastatic
Efficacy and Safety of DEB-TACE Combined With HAIC Versus HAIC Alone in Patients With Unresectable CRLM
Retrospective evaluation of the efficacy and safety of DEB-TACE combined with HAIC versus HAIC alone in patients with unresectable colorectal liver metastases (CRLM)
- Trial name
- NCT07031570
- Volunteers
- 500 people
- Sponsor
- Peking University Cancer Hospital & Institute
Childhood Central Nervous System Germ Cell Tumor, Childhood Extragonadal Germ Cell Tumor
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
This phase II trial is studying how well oxaliplatin works in treating young patients with recurrent solid tumors that have not responded to previous treatment.
- Conditions
- Childhood Central Nervous System Germ Cell Tumor, Childhood Extragonadal Germ Cell Tumor, Childhood Hepatoblastoma, Childhood Hepatocellular Carcinoma
- Trial name
- NCT00091182
- Testing
- oxaliplatin
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer Metastatic
Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis
Microdevices have been used to ascertain in vivo drug response, which can lead to improved cancer treatment delivery; however, they have not been evaluated for liver tumors.
- Trial name
- NCT07193862
- Testing
- Doxorubicin, FOLFOX, Botensilimab, Balstilimab, Bevacizumab, FOLFIRI, FOLFIRINOX, AGEN2373
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Northwell Health
Mediastinal Tumours and Lymph Nodes, Celiac, Perigastric and Peri-pancreatic Lymph Nodes
Controlled Trial Comparing the Performance of 22 Gauge Versus 25 Gauge EUS-FNA Needles (FNA-22G-25G)
The aim of the study is to compare the performance characteristics of EUS-FNA 22 Gauge needle and EUS FNA 25 Gauge needle in terms of cellularity and diagnostic yield for diagnosis of various pathologies, including lymph nodes…
- Conditions
- Mediastinal Tumours and Lymph Nodes, Celiac, Perigastric and Peri-pancreatic Lymph Nodes, Pancreatic Masses, Liver Masses
- Trial name
- NCT01016288
- Where
- 9 sites in Denmark, Germany and 1 more
- Volunteers
- 135 people
- Sponsor
- University Hospital, Gentofte, Copenhagen
Hepatocellular Carcinoma
A Trial Utilizing 18F-FS PG PET to Guide Therapy in Hepatocellular Carcinoma
To evaluate the relationship between 18F-FSPG uptake in HCC lesions, ctDNA in blood and clinical response to Y90 radioembolization therapy in patients with hepatocellular carcinoma (HCC) by SOC imaging.
- Trial name
- NCT07116486
- Testing
- Radiopharmaceutical 18F-FSPG
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Cholangiocarcinoma, Liver Neoplasms
Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma
This pilot clinical trial studies the safety and effectiveness of continuous hepatic arterial infusion (HAI) of floxuridine (FUDR) alone or in combination with other chemotherapeutic drugs in treating patients with locally…
- Trial name
- NCT01525069
- Testing
- Floxuridine, Dexamethasone, Gemcitabine
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Washington University School of Medicine
Hepatocellular Carcinoma
TACE With Dicycloplatin(TP21) in Unresectable HCC
To evaluate the effectiveness and safety of TP21 injection for TACE in treatment of hepatocellular carcinoma: 1. Primary efficacy endpoint: progression-free survival (PFS), which will be assessed by the Independent Review…
- Trial name
- NCT05472896
- Testing
- cTACE, Dicycloplatin (TP21), Epirubicin
- Where
- China
- Volunteers
- 332 people
- Sponsor
- Gao-jun Teng
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.